Moderna to Ask for Clearance for Combination COVID-Influenza Vaccine

The company says positive results from a clinical trial is spurring the move.

A health care worker prepares a vaccine in New York City in a file photograph. Michael M. Santiago/Getty Images

Moderna is going to ask regulators to approve its combination vaccine against COVID-19 and influenza, the company said on June 30.

The company said a phase 3 study evaluating its influenza vaccine candidate, mRNA-1010—which utilizes the same messenger ribonucleic acid (mRNA) platform as its COVID-19 vaccine—showed positive effectiveness.